Figure 4
Anti-CD20 and anti-CD137 mAbs combination activity is enhanced by sequential mAb administration. C57BL/6 mice were inoculated with 5 × 106 BL3750 lymphoma tumor cells subcutaneously on the abdomen. After tumor inoculation, mice received rat IgG control on day 3 (●), anti-CD20 mAb on day 3 and anti-CD137 mAb on day 4 (▴), or anti-CD20 mAb on day 3 and anti-CD137 mAb on day 3 (■). Mice (10 per group) were then monitored for tumor growth (A; *P < .001) and overall survival (B; * P = .001).
